Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutegrid.4714.6t, Stockholm, Sweden.
Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Microbiol Spectr. 2021 Oct 31;9(2):e0144021. doi: 10.1128/Spectrum.01440-21. Epub 2021 Oct 6.
Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects. The activity of omadacycline and five comparators was assessed with agar dilution on a 2015-to-2018 collection of 65 C. difficile isolates from Sweden. Omadacycline demonstrated activity against the contemporary ribotypes of C. difficile, and further clinical investigation is needed. Evaluating the activity of novel antimicrobials like omadacycline is of great interest, as a reliable and efficient antimicrobial treatment for Clostridioides difficile infections is in demand.
艰难梭菌感染是一个日益严峻的临床挑战。新型化合物奥马环素是一种有潜力的治疗选择，因为许多抗生素由于成本和副作用的原因，其活性有限或很少使用。奥马环素和五种对照药物的活性通过琼脂稀释法在 2015 年至 2018 年期间从瑞典采集的 65 株艰难梭菌分离株中进行了评估。奥马环素对当前艰难梭菌的核糖体型具有活性，需要进一步的临床研究。评估奥马环素等新型抗菌药物的活性具有重要意义，因为人们迫切需要一种可靠和有效的抗艰难梭菌感染的抗菌治疗方法。
